Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- 25OHD3 RM 3 CYP-2R1 27B1 24A1 FGF-23
- Product Overview:
25-hydroxy Vitamin D3 is an intermediate in the biosynthesis of 1?,25-dihydroxy vitamin D3 (calcitriol; Item No. 71820), a vitamin D receptor (VDR) agonist that has multiple functions, including stimulation of calcium absorption, insulin secretion, and cell proliferation and differentiation.{60080,60081,60082} It is produced from vitamin D3 (Item No. 11792) by 25-hydroxylase/CYP2R1 and bound to vitamin D binding protein (DBP) and albumin in the liver, then secreted into the bloodstream where it is the major circulating form of vitamin D.{60080} 25-hydroxy Vitamin D3 is transported to the kidney where it is hydroxylated by 1?-hydroxylase/CYP27B1 or 24-hydroxylase/CYP24A1 to produce 1?,25-dihydroxy vitamin D3 or 24,25-dihydroxy vitamin D3, respectively. Conversion of 25-hydroxy vitamin D3 to 1?,25-dihydroxy vitamin D3 is stimulated by parathyroid hormone (PTH) and inhibited by calcium, phosphorus, or FGF23. Serum 25-hydroxy vitamin D3 levels have been widely used as a marker of vitamin D status.{60081} Increased serum 25-hydroxy vitamin D3 levels are associated with increased bone density in patients with osteoarthritis, as well as reduced risk of colorectal, breast, and prostate cancer, whereas decreased serum 25-hydroxy vitamin D3 levels have been found in children with nutritional rickets, a condition caused by vitamin D deficiency and characterized by reduced bone density.{60081,60083,60084} Cayman’s 25-hydroxy Vitamin D3 Rabbit Monoclonal Antibody can be used for ELISA.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.